• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Risk of severe COVID in solid organ transplant recipient.实体器官移植受者发生严重 COVID 的风险。
Rev Esp Quimioter. 2023 Nov;36 Suppl 1(Suppl 1):15-17. doi: 10.37201/req/s01.04.2023. Epub 2023 Nov 24.
2
SARS-CoV-2 vaccination in solid-organ transplant recipients: What the clinician needs to know.SARS-CoV-2 疫苗接种在实体器官移植受者中的应用:临床医生需要了解的知识。
Transpl Int. 2021 Oct;34(10):1776-1788. doi: 10.1111/tri.14029. Epub 2021 Sep 20.
3
Reduction in the risk of progression of solid organ transplant recipients infected by SARS-CoV-2 treated with monoclonal antibodies.降低 SARS-CoV-2 感染的实体器官移植受者进展为重症的风险:单克隆抗体治疗的作用
Rev Esp Quimioter. 2023 Aug;36(4):380-391. doi: 10.37201/req/023.2023. Epub 2023 Apr 24.
4
COVID-19 and solid organ transplantation: Finding the right balance.COVID-19 与实体器官移植:寻找平衡。
Transplant Rev (Orlando). 2022 Jul;36(3):100710. doi: 10.1016/j.trre.2022.100710. Epub 2022 Jul 4.
5
The Immunology of SARS-CoV-2 Infection and Vaccines in Solid Organ Transplant Recipients.实体器官移植受者中 SARS-CoV-2 感染和疫苗的免疫学
Viruses. 2021 Sep 20;13(9):1879. doi: 10.3390/v13091879.
6
Vaccination Against SARS-CoV-2 in Lung Transplant Recipients: Immunogenicity, Efficacy and Safety.新型冠状病毒疫苗在肺移植受者中的免疫原性、疗效和安全性。
Front Immunol. 2022 Jun 1;13:906225. doi: 10.3389/fimmu.2022.906225. eCollection 2022.
7
Breakthrough COVID-19 after SARS-CoV-2 vaccination in solid organ transplant recipients: An analysis of symptomatic cases and monoclonal antibody therapy.SARS-CoV-2 疫苗接种后突破 COVID-19 在实体器官移植受者中的发生:症状病例分析和单克隆抗体治疗。
Transpl Infect Dis. 2022 Apr;24(2):e13779. doi: 10.1111/tid.13779. Epub 2022 Jan 31.
8
Immune Response after the Fourth Dose of SARS-CoV-2 mRNA Vaccine Compared to Natural Infection in Three Doses' Vaccinated Solid Organ Transplant Recipients.接种三剂 SARS-CoV-2 mRNA 疫苗的实体器官移植受者与自然感染相比的第四剂后免疫反应。
Viruses. 2022 Oct 19;14(10):2299. doi: 10.3390/v14102299.
9
An overview of COVID-19 in solid organ transplantation.COVID-19 在实体器官移植中的概述。
Clin Microbiol Infect. 2022 Jun;28(6):779-784. doi: 10.1016/j.cmi.2022.02.005. Epub 2022 Feb 18.
10
SARS-CoV-2 anti-spike antibodies after a fourth dose of COVID-19 vaccine in adult solid-organ transplant recipients.COVID-19 疫苗第四剂接种后成人实体器官移植受者的 SARS-CoV-2 刺突抗体。
Vaccine. 2022 Oct 19;40(44):6404-6411. doi: 10.1016/j.vaccine.2022.08.065. Epub 2022 Sep 6.

引用本文的文献

1
Antibody Response to SARS-CoV-2 Vaccines in Transplant Recipients and Hemodialysis Patients: Data from the Dominican Republic.移植受者和血液透析患者对SARS-CoV-2疫苗的抗体反应:来自多米尼加共和国的数据。
Vaccines (Basel). 2024 Nov 23;12(12):1312. doi: 10.3390/vaccines12121312.

本文引用的文献

1
Best practices during COVID-19 pandemic in solid organ transplant programs in Spain.西班牙实体器官移植项目在 COVID-19 大流行期间的最佳实践。
Transplant Rev (Orlando). 2023 Jan;37(1):100749. doi: 10.1016/j.trre.2023.100749. Epub 2023 Feb 3.
2
Immunodeficiency syndromes differentially impact the functional profile of SARS-CoV-2-specific T cells elicited by mRNA vaccination.免疫缺陷综合征会对 mRNA 疫苗引发的 SARS-CoV-2 特异性 T 细胞的功能谱产生不同影响。
Immunity. 2022 Sep 13;55(9):1732-1746.e5. doi: 10.1016/j.immuni.2022.07.005. Epub 2022 Jul 19.
3
Decline in Antibody Concentration 6 Months After Two Doses of SARS-CoV-2 BNT162b2 Vaccine in Solid Organ Transplant Recipients and Healthy Controls.接受两剂 BNT162b2 疫苗 6 个月后,实体器官移植受者和健康对照者的抗体浓度下降。
Front Immunol. 2022 Feb 23;13:832501. doi: 10.3389/fimmu.2022.832501. eCollection 2022.
4
Neutralization against Omicron variant in transplant recipients after three doses of mRNA vaccine.mRNA 疫苗三剂接种后移植受者对奥密克戎变异株的中和作用
Am J Transplant. 2022 Aug;22(8):2089-2093. doi: 10.1111/ajt.17020. Epub 2022 Mar 21.
5
Real-world Effectiveness of the Pfizer-BioNTech BNT162b2 and Oxford-AstraZeneca ChAdOx1-S Vaccines Against SARS-CoV-2 in Solid Organ and Islet Transplant Recipients.辉瑞-生物科技/BioNTech BNT162b2 疫苗和牛津大学-阿斯利康 ChAdOx1-S 疫苗在实体器官和胰岛移植受者中预防 SARS-CoV-2 的真实世界效果。
Transplantation. 2022 Mar 1;106(3):436-446. doi: 10.1097/TP.0000000000004059.
6
Humoral and cellular immune responses to the SARS-CoV-2 BNT162b2 vaccine among a cohort of solid organ transplant recipients and healthy controls.体液和细胞免疫应答在 Sars-CoV-2 BNT162b2 疫苗接种的实体器官移植受者和健康对照者中的作用。
Transpl Infect Dis. 2022 Feb;24(1):e13772. doi: 10.1111/tid.13772. Epub 2021 Dec 21.
7
Negative immune responses to two-dose mRNA COVID-19 vaccines in renal allograft recipients assessed with simple antibody and interferon gamma release assay cellular monitoring.用简单抗体和干扰素γ释放试验细胞监测评估肾移植受者对两剂 mRNA COVID-19 疫苗的阴性免疫反应。
Am J Transplant. 2022 Mar;22(3):786-800. doi: 10.1111/ajt.16854. Epub 2021 Oct 7.
8
SARS-CoV2-specific Humoral and T-cell Immune Response After Second Vaccination in Liver Cirrhosis and Transplant Patients.肝硬化和肝移植患者第二次接种后针对 SARS-CoV2 的体液和 T 细胞免疫应答。
Clin Gastroenterol Hepatol. 2022 Jan;20(1):162-172.e9. doi: 10.1016/j.cgh.2021.09.003. Epub 2021 Sep 9.
9
Adaptive lymphocyte profile analysis discriminates mild and severe forms of COVID-19 after solid organ transplantation.适应性淋巴细胞谱分析可区分实体器官移植后 COVID-19 的轻、重症形式。
Kidney Int. 2021 Oct;100(4):915-927. doi: 10.1016/j.kint.2021.05.032. Epub 2021 Jun 11.
10
The association between severe or death COVID-19 and solid organ transplantation: A systematic review and meta-analysis.严重或致死 COVID-19 与实体器官移植的关联:系统评价和荟萃分析。
Transplant Rev (Orlando). 2021 Jul;35(3):100628. doi: 10.1016/j.trre.2021.100628. Epub 2021 May 21.

实体器官移植受者发生严重 COVID 的风险。

Risk of severe COVID in solid organ transplant recipient.

机构信息

Pablo Barreiro MD PhD, Regional Public Health Laboratory. Comunidad de Madrid. Infectious Diseases. Internal Medicine. Hospital General Universitario La Paz. Madrid, Spain. Department of Medical Specialties and Public Health. School of Medicine. Universidad Rey Juan Carlos, 28922 Madrid, Spain.

出版信息

Rev Esp Quimioter. 2023 Nov;36 Suppl 1(Suppl 1):15-17. doi: 10.37201/req/s01.04.2023. Epub 2023 Nov 24.

DOI:10.37201/req/s01.04.2023
PMID:37997864
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10793554/
Abstract

Despite the fact that COVID is today not a life-threat for the general population, recipients of solid organ transplantation should be viewed as a high risk group for severe COVID. Repetitive doses of SARS-CoV-2 vaccine still fail to protect SOT recipients from infection, disease or even death caused by COVID. A more frequent need for medical care may initially place these patients at greater chances of SARS-CoV-2 infection. Immunosuppression after engrafting and underlying medical conditions that led to the practice of SOT contribute to more risk of severe infection. Immunosuppression also blunts the intensity of humoral and cellular responses after vaccination, even when several booster doses have been administered. Still, vaccination is the best strategy to prevent a fatal outcome in case of SARS-CoV-2 infection, with a particular reduction in mortality. SOT recipients should be considered a high-risk population that need yearly SARS-CoV-2 vaccination.

摘要

尽管 COVID 如今对普通人群来说已不构成生命威胁,但实体器官移植受者应被视为 COVID 重症的高危人群。重复接种 SARS-CoV-2 疫苗仍然不能保护 SOT 受者免受 COVID 感染、疾病甚至死亡的影响。更频繁的医疗需求可能最初会使这些患者面临更大的感染 SARS-CoV-2 的风险。移植后免疫抑制和导致 SOT 实践的基础医学状况导致更严重感染的风险增加。免疫抑制还会削弱接种疫苗后体液和细胞反应的强度,即使已经接种了几剂加强针。尽管如此,接种疫苗仍然是预防 SARS-CoV-2 感染导致致命后果的最佳策略,尤其是可以降低死亡率。SOT 受者应被视为高危人群,需要每年接种 SARS-CoV-2 疫苗。